65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03663933
(ClinicalTrials.gov)
September 4, 20187/9/2018Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationPhase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationLymphoproliferative Disorders;Autoimmune Lymphoproliferative;Primary T-cell Immunodeficiency Disorders;Immune System Diseases;Common Variable ImmunodeficiencyDrug: Immunosuppression Only Conditioning;Drug: Reduced Intensity Conditioning;Drug: GVHD Prophylaxis;Procedure: Allogeneic HSCNational Cancer Institute (NCI)NULLRecruiting4 YearsN/AAll177Phase 2United States
2NCT02579967
(ClinicalTrials.gov)
November 19, 201516/10/2015Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesPilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesPrimary T-cell Immunodeficiency Disorders;Common Variable Immunodeficiency;Immune System Diseases;Autoimmune Lymphoproliferative;Lymphoproliferative DisordersDrug: Immunosuppression Only Conditioning -Closed with amendment L;Drug: Reduced Intensity Conditioning;Drug: Myeloablative Conditioning-Closed with amendment L;Drug: GVHD Prophylaxis;Procedure: Allo BMTNational Cancer Institute (NCI)NULLRecruiting4 Years75 YearsAll224Phase 2United States